WilmerHale advised Ratio Therapeutics Inc, a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, on its exclusive worldwide license and collaboration agreement for the development of a Somatostatin Receptor 2 (SSTR2) radiotherapeutic candidate for cancer. Under the terms of the agreement, Ratio will receive combined upfront and potential milestone payments of up to $745M and is eligible to receive tiered royalty payments.

Sarah Hogan, Lauren Leonard and Jenna Ventorino represented Ratio on the transaction, with Stuart Falber and Rebecca Nauta advising on corporate matters, Fred Adam advising on tax matters, Bruce Manheim advising on FDA matters and Heather Petruzzi advising on IP matters.